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detter to the Editor
ortality beneﬁt and reduced need for repeat
evascularization with statin therapy among
atients undergoing percutaneous coronary
ntervention
o the Editor:
In their article on statin therapy for patients with coro-
ary artery disease, [1] Nakamura and colleagues discussed
he effect of statin therapy on all-cause mortality, target
esion revascularization (TLR), and a composite endpoint
f death, myocardial infarction, and readmission for heart
ailure among a prespeciﬁed subgroup of patients undergo-
ng percutaneous coronary intervention (PCI). Their ﬁndings
howed a discrepancy between mortality and cardiovascu-
ar events. Statin therapy decreased the risk of fatal events,
ut not TLR, or the composite triple endpoint. However, we
hink that these results need to be cautiously interpreted
ecause a not ideal adjustment of confounding by indica-
ion together with insufﬁcient power may have affected the
alidity and precision of their effect estimates.
Although the association between statin therapy and
ll-cause mortality among PCI-patients were statistically
igniﬁcant in this study, the reported magnitude of protec-
ion, in our opinion, may have been overestimated. Based
n a cohort of PCI-patients with similar enrollment peri-
ds (February 2004 to May 2004; February 2006 to July
006) from the US National Heart, Lung, and Blood Institute
NHLBI) Dynamic Registry, 83% of whom received at least one
rug-eluting stent, we found a reduction of 42% in all-cause
ortality [2] as compared with 73% in their study. It is note-
orthy that up to today no clinical trials have conﬁrmed the
ortality beneﬁt of statins among PCI-patients [3].
On the other hand, their evidence of lack of effect on TLR
r the composite endpoint of cardiac events seems unreli-
ble. Given the observed effect on mortality, it could not
e explained only by false negatives due to small sample
ize. Based on the NHLBI Dynamic Registry, we found post-
ischarge statin therapy signiﬁcantly reduced the need for
epeat revascularization after adjusting for a wide array of
ovariates via propensity score models (hazard ratio: 0.74,
5% conﬁdence interval: 0.56—1.00, P = 0.05) [2]. A meta-
nalysis of randomized clinical trials consistently showed a
imilar magnitude of reduction in repeat revascularization
ith statin therapy which was initiated after PCI proce-
ures (risk ratio: 0.73, 95% conﬁdence interval: 0.55—0.98,
= 0.04) [3].
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914-5087/$ — see front matter © 2011 Japanese College of Cardiology.As the authors pointed out in the Discussion, confound-
ng cannot be completely controlled in an observational
tudy due to unobserved covariates. Notably, several impor-
ant prognostic factors in Tables 1 and 3 were not adjusted
n their ﬁnal multivariate model, although signiﬁcant dif-
erences were observed between treatment groups. Small
ample size may have limited the ability of a statistical
odel to accommodate covariates as needed. In this sense,
djustment through propensity score approach could possi-
ly be an appropriate method to deal with their scenario [4].
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We appreciate Dr Zhang’s interest in our study [1] and the
pportunity to discuss some issues. We also congratulate Dr
hang and coworkers for their studies of the US National
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